Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP

References

• Cancer Incidence in Jordan. Available from: www.moh.gov.jo//c602eda7-0c36-49cd-bea1-3484e46c0b97. Accessed September 4, 2022.
   Google Scholar
• Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2008;2008:349–358. doi:10.1182/asheducation-2008.1.349
   Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–862. doi:10.1084/jem.20031074
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol. 1993;11(12):2306–2313. doi:10.1200/JCO.1993.11.12.2306
   PubMed Web of Science ®Google Scholar
• Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014;9(3):273–283. doi:10.1007/s11899-014-0219-0
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–3879. doi:10.1182/blood-2003-06-1841
   PubMed Web of Science ®Google Scholar
• Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–2065. doi:10.1182/blood-2013-10-535443
   PubMed Web of Science ®Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–2669. doi:10.1182/blood-2011-05-326538
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130(5):691–699. doi:10.1111/j.1365-2141.2005.05661.x
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372–376. doi:10.1038/sj.bjc.6601460
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258–1264.
   PubMed Web of Science ®Google Scholar
• Avigdor A, Sirotkin T, Kedmi M, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol. 2014;93(8):1297–1304. doi:10.1007/s00277-014-2043-y
   PubMed Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123–130. doi:10.1093/annonc/mdj030
   PubMed Web of Science ®Google Scholar
• Rieger M, Österborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera international trial group study. Ann Oncol. 2011;22(3):664–670. doi:10.1093/annonc/mdq418
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693. doi:10.1182/blood.v99.8.2685
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416. doi:10.1056/NEJMoa1214561
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):298–303. doi:10.1182/asheducation-2017.1.298
   PubMedGoogle Scholar
• Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896–1903. doi:10.1200/JCO.2009.26.5942
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM199309303291402
   PubMed Web of Science ®Google Scholar
• Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v91–v102. doi:10.1093/annonc/mdw175
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British society for haematology good practice paper. Br J Haematol. 2019;185(3):402–409. doi:10.1111/bjh.15731
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines® insights: b-cell lymphomas, version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218–1230. doi:10.6004/jnccn.2021.0054
   PubMed Web of Science ®Google Scholar
• Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534–544. doi:10.1111/bjh.15051
   PubMed Web of Science ®Google Scholar
• Zhou H, Xu-Monette ZY, Xiao L, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020;10(5):49. doi:10.1038/s41408-020-0312-7
   PubMed Web of Science ®Google Scholar
• Morgenstern Y, Aumann S, Goldschmidt N, Gatt ME, Nachmias B, Horowitz NA. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: results of a bi-center retrospective study. Cancer Med. 2021;10(24):8866–8875. doi:10.1002/cam4.4387
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17(2):239–249. doi:10.1634/theoncologist.2011-0275
   PubMed Web of Science ®Google Scholar
• Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020;136(24):2803–2811. doi:10.1182/blood.2019004296
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood. 2018;132(8):782–790. doi:10.1182/blood-2018-04-791566
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329–1336. doi:10.1080/10428190802108870
   PubMed Web of Science ®Google Scholar
• Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (Thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018;24(10):2133–2138. doi:10.1016/j.bbmt.2018.06.009
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. PMID: 34891224. doi:10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. doi:10.1016/S0140-6736(22
   PubMed Web of Science ®Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291–3299. doi:10.1200/JCO.19.01389
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkMate 436 study. J Clin Oncol. 2019;37(33):3081–3089. doi:10.1200/JCO.19.01492
   PubMed Web of Science ®Google Scholar
• IELSG37. A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL). Available from: https://clinicaltrials.gov/ct2/show/NCT01599559. Accessed December 12, 2022.
   Google Scholar